运动训练对乳腺癌蒽环类化疗女性心脏毒性及心脏健康结局的影响:随机对照试验研究方案
本方案为双臂前瞻性随机对照试验,计划纳入90例接受蒽环类化疗的早期乳腺癌成年女性,按1:1随机分配至监督下运动干预组或标准照护对照组。干预组在化疗期间每周进行3次有氧联合抗阻训练,主要结局为NT-proBNP、左室纵向应变和左室射血分数,旨在探讨运动减轻蒽环类相关心脏毒性的效果。
要点
- 拟纳入90例接受蒽环类化疗的早期乳腺癌女性,1:1随机分为运动干预组与标准照护组。
- 干预组化疗期间每周3次监督下有氧联合抗阻训练,强度与量渐进增加。
- 主要结局为NT-proBNP、静息左室纵向应变和静息左室射血分数,于基线、化疗结束及结束后3个月评估。
核心结论
- 本试验方案拟通过新型临床生物标志物确定结构化运动干预减轻蒽环类相关心脏毒性的效果,总体目标是寻找进一步改善乳腺癌照护的手段。
研究设计与样本
- 本方案描述一项双臂前瞻性随机对照试验,探索结构化运动方案对接受含蒽环类化疗的乳腺癌女性的心脏保护作用。
- 计划纳入90例接受蒽环类化疗的早期乳腺癌成年女性,按1:1随机分配至干预组或对照组。
- 干预组在蒽环类化疗期间每周进行3次监督下运动,由有氧与抗阻训练组合而成,强度和量渐进增加。
- 对照组接受标准乳腺癌照护。
- 数据于基线(t0)、蒽环类治疗结束后(t2)及t2后3个月(t3)获取;NT-proBNP另于每个蒽环类治疗周期前1–24小时(t1)测量。
关键数值与推荐
- 主要结局为循环N末端脑钠肽前体(NT-proBNP)水平、静息左室纵向应变和静息左室射血分数。
- 次要结局包括静息血压、静息心率(HR)、静息心率变异性(HRV)、恢复心率、身体功能结局、自报身体活动水平、健康相关生活质量及疲劳。
- 试验注册号ISRCTN32617901,2018年10月24日注册,2019年1月11日最后更新。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出,关于运动降低蒽环类相关心脏毒性的多数数据来自动物研究,仅少数研究在有限数量患者中显示有益效应。
- 原文指出,为更好理解运动减轻蒽环类相关心脏毒性的有效性,临床真实世界试验需要更大样本量和更准确、更有价值的临床生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anthracyclines are chemotherapeutic agents frequently used in breast cancer (BC) treatment. Although it improves disease-free and overall survival, the use of anthracyclines is associated with a cumulative risk of cardiac toxicity. Preventive strategies to optimize cardiac health are needed and exercise is proposed as a potential non-pharmacological approach for counteracting anthracycline-related cardiotoxicity (ARC). Most of the data on the effects of exercise to reduce ACT are from animal studies, with only a few studies in a limited number of patients indicating beneficial effects. To better understand the effectiveness of exercise in the mitigation of ARC, clinical, real-world trials claim require a larger sample size and more accurate and valuable clinical biomarkers. In this study, we intend to include a large sample and investigate cardiac function through serial measures of biomarkers and imaging techniques. METHODS: This protocol describes a two-arm, prospective, randomized controlled trial that will explore the cardioprotective effect of a structured exercise program in women with BC undergoing anthracycline-containing chemotherapy (ACT). Ninety adult women with early BC and recommended to receive ACT will be randomly assigned (1:1) to an intervention group or a control group. Patients allocated to the intervention group will perform a supervised exercise program three times per week, consisting of a combination of aerobic and resistance training with progressive intensity and volume, during the time period they receive ACT. The control group will receive standard BC care. Primary outcomes related to cardiac (dys)function will be circulating N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, resting left ventricular (LV) longitudinal strain, and resting LV ejection fraction. Secondary outcomes will include the assessment of resting blood pressure, resting heart rate (HR), resting HR variability (HRV), recovery HR, physical function outcomes, self-reported physical activity level, health-related quality of life, and fatigue. Data will be obtained at baseline (t0), after the end of anthracycline-treatment (t2), and 3 months after t2 (t3). Additionally, NT-proBNP will be measured 1-24 h prior to each anthracycline-treatment cycle (t1). DISCUSSION: The implementation of the present study design, using novel clinical biomarkers, will determine the effect of structured exercise interventions at mitigating ARC, with the overall aim of finding means to further improve BC care. TRIAL REGISTRATION: ISRCTN, ISRCTN32617901 . Registered on 24 October 2018. Last updated on 11 January 2019.
引用
- Antunes P, Esteves D, Nunes C, et al. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial. Trials. 2019. PMID: 31307527. doi:10.1186/s13063-019-3499-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。